Zydus gets DCGI nod for drug to treat anaemia associated with chronic kidney disease

Zydus Lifesciences on Monday said it has received an approval from the Drug Controller General of India (DCGI) for Oxemia (Desidustat), a first-of-its-kind oral treatment for anaemia associated with chronic kidney disease (CKD). The drug firm, formerly known as Cadila Healthcare, said it has received approval for its new drug application (NDA) the product.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CI3vqOX
via IFTTT